

Blood has all the answers
 Liquid biopsy has the potential to revolutionize cancer management, with frequent testing of blood samples in search for content released by a tumour.

Tumor Cell

ctDNA


miRNA

Exosomes

Sample preparation is critical

The challenge is that blood content is rare and unstable. So, there is a strong clinical need for standardized technologies securing high quality samples for reliable diagnosis.

- Our goal is to make liquid biopsy widely available into clinical practice -



SBS

Proprietary nanocoated slides

- Immediate and **spontaneous adhesion** of otherwise non-adherent cells
- **No enrichment**: allows shear stress free collection of the entire white blood cells (WBC) fraction of a blood sample with no bias
- Uniform distribution of cells as a single monolayer resembling a **two-dimensional tissue slide**
- Use of standard tissue assays (IF, IHC, FISH) and AI driven imaging to **detect and characterize circulating tumor cells (CTCs)**

Tethis Approach

See.d

Proprietary sample preparator

- **Automated, standardized, gentle preparation** of the blood sample at the point of collection (overcoming content instability issues)
 - **No need for specialized technicians**
- **WBC stabilization** on SBS slides for subsequent CTC analysis
- **Plasma separation** for analysis of ctDNA from the same blood sample



Future Proof Technology

Sample is perfectly suitable to benefit from ongoing technological advancements (AI digital pathology, spatial biology, multiplexing, multi-omics...)

Clinically Validated

Pilot study published on a peer-review paper and conducted in collaboration with **University of Basel** shows **very high sensitivity and specificity** on challenging setting of early stage breast cancer detection.

